drugset / Trial / NCT03866434
Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, open-label, single-sequence, non-randomized, multiple-dose, crossover pharmacokinetic study is a single site study in the United States and will be conducted to assess the effect of a CYP1A2 inducer (omeprazole 40 mg once daily \[QD\]) on the pharmacokinetics of anagrelide (1 mg) when administered concurrently in healthy participants.
Timeline
- Start
- 2019-02-26
- Primary completion
- 2019-04-10
- Completion
- 2019-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |
| Subject | SPD422 | Unknown | 1 mg | Oral |
Indications
No indication recorded.